Access and Norgine to partner on MuGard in European territories

Emerging biopharma company Access Pharmaceuticals has entered into an exclusive license agreement with Norgine, a European specialty pharma company, to commercialize its oral mucositis therapy MuGard in Europe.

Access will receive $10 million in milestone payments and an escalating royalty on the net sales of Mugard in licensed territories. Norgine will develop, manufacture and commercialize the product in the European Union, Switzerland, Norway, Iceland and Lichtenstein, with an anticipated launch date in 2015.

Jeffrey Davis, chief executive of Access, said: "With product offerings in complementary therapeutic areas and an established presence in the cancer supportive care space, Norgine is an ideal partner for us and we believe this partnership will drive commercial adoption in Europe and facilitate access of a proven treatment option to help protect patients from oral mucositis, a debilitating side effect."